Company presents interim results of AIDS treatment clinical trials. (Passive Hyperimmune Therapy) (HemaCare Corporation)

Joshua Levy, M.D., medical director of HemaCare Corporation, Los Angeles, California, reported the six-month, interim results of the company's controlled, clinical trials of Passive Hyperimmune Therapy (PHT) to the 5th National Forum on AIDS, Hepatitis and Other Blood-Borne Diseases.

The Forum was sponsored by the National Foundation for Infectious Diseases in collaboration with the U.S. Centers for Disease Control and the U.S. National Institute of Allergy and Infectious Diseases.

Levy, principal investigator of the study which involved 18 clinical co-investigators, six participating hospitals and 219 patients, stated in his presentation that patients …